Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 5/20 | 0.47 |
| ▸ | RXRB | P28702 | 5/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | UNG | P13051 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 2/20 | 0.40 |
| ▸ | RARG | P13631 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13963487 | 0.85 | MAPT (0.40) | SMN1; SMN2MAPTTDP1TP53CYP3A4 | |
| SCHEMBL166878 | 0.82 | RXRB (0.59) | SMN1; SMN2MAPTTDP1TP53CYP3A4 | |
| SCHEMBL501957 | 0.82 | RXRB (0.64) | SMN1; SMN2MAPTTDP1TP53CYP3A4 | |
| SCHEMBL2997840 | 0.81 | CES2 (0.48) | SMN1; SMN2RXRARXRBRXRGUNG | |
| SCHEMBL15123374 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2MAPTTDP1TP53CYP3A4 | |
| SCHEMBL13267157 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTTDP1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL11879619 | 0.80 | RXRB (0.57) | SMN1; SMN2MAPTTDP1TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL4585979 | 0.80 | RXRB (0.57) | SMN1; SMN2MAPTTDP1TP53CYP3A4 | |
| Water SCHEMBL28383353 | 0.80 | RXRB (0.57) | SMN1; SMN2MAPTTDP1TP53CYP3A4 | |
| SCHEMBL5873298 | 0.80 | RXRB (0.62) | SMN1; SMN2MAPTTDP1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143425-A1 | IMPROVEMENTS RELATED TO SORBENT MEDIA | GENESIS SYSTEMS LLC | 2023-05-11 | — | — | US | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-4827026-A | COBALT, BROMINE, MANGANESE CATALYST | AMOCO CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | VHL, FLT4, FLT1 | SMN1; SMN2 3031/4885MAPT 3579/4885TDP1 1036/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | SMN1; SMN2 2833/4885MAPT 3310/4885TDP1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.